These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 22232278

  • 21. Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
    García-de-la-Mària C, Marco F, Armero Y, Soy D, Moreno A, del Río A, Almela M, Cervera C, Ninot S, Falces C, Mestres CA, Gatell JM, Jiménez de Anta MT, Miró JM, Hospital Clínic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2781-6. PubMed ID: 20421394
    [Abstract] [Full Text] [Related]

  • 22. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.
    Wootton M, MacGowan AP, Walsh TR.
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4195-7. PubMed ID: 17043121
    [Abstract] [Full Text] [Related]

  • 23. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP.
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3789-93. PubMed ID: 16127054
    [Abstract] [Full Text] [Related]

  • 24. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW, Abdul Momin HF, Phee LM, Wareham DW.
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [Abstract] [Full Text] [Related]

  • 25. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR, Yim J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [Abstract] [Full Text] [Related]

  • 26. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.
    Barnea Y, Navon-Venezia S, Kuzmenko B, Artzi N, Carmeli Y.
    Eur J Clin Microbiol Infect Dis; 2014 Mar; 33(3):325-9. PubMed ID: 24030718
    [Abstract] [Full Text] [Related]

  • 27. The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis.
    García-de-la-Mària C, Gasch O, García-Gonzalez J, Soy D, Shaw E, Ambrosioni J, Almela M, Pericàs JM, Tellez A, Falces C, Hernandez-Meneses M, Sandoval E, Quintana E, Vidal B, Tolosana JM, Fuster D, Llopis J, Pujol M, Moreno A, Marco F, Miró JM.
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610194
    [Abstract] [Full Text] [Related]

  • 28. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM.
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [Abstract] [Full Text] [Related]

  • 29. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
    Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang SJ.
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5528-33. PubMed ID: 22890759
    [Abstract] [Full Text] [Related]

  • 30. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
    Hegde SS, Okusanya OO, Skinner R, Shaw JP, Obedencio G, Ambrose PG, Blais J, Bhavnani SM.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
    [Abstract] [Full Text] [Related]

  • 31. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.
    Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.
    J Antimicrob Chemother; 2014 Nov; 69(11):3006-10. PubMed ID: 24990867
    [Abstract] [Full Text] [Related]

  • 32. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR.
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [Abstract] [Full Text] [Related]

  • 33. In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
    Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Majcherczyk P, Moreillon P.
    Antimicrob Agents Chemother; 2011 Sep; 55(9):3977-84. PubMed ID: 21730114
    [Abstract] [Full Text] [Related]

  • 34. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ.
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM, García-de-la-Mària C, Armero Y, de-Lazzari E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jiménez-de-Anta MT, Marco F, Hospital Clínic Experimental Endocarditis Study Group.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 37. In vitro identification of underutilized β-lactam combinations against methicillin-resistant Staphylococcus aureus bacteremia isolates.
    Davis KP, McDermott LA, Snydman DR, Aldridge BB.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0097624. PubMed ID: 38916355
    [Abstract] [Full Text] [Related]

  • 38. Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Infective Endocarditis.
    Save J, Que YA, Entenza J, Resch G.
    Viruses; 2022 Aug 16; 14(8):. PubMed ID: 36016414
    [Abstract] [Full Text] [Related]

  • 39. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K.
    Antimicrob Agents Chemother; 2010 Jan 16; 54(1):116-25. PubMed ID: 19884364
    [Abstract] [Full Text] [Related]

  • 40. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
    Voorn GP, Kuyvenhoven J, Goessens WH, Schmal-Bauer WC, Broeders PH, Thompson J, Michel MF.
    Antimicrob Agents Chemother; 1994 Mar 16; 38(3):487-93. PubMed ID: 8203842
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.